PA

sponsor

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09

Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in pts with type 2 diabetes is confirmed to increase risk of heart failure and of some fractures, mainly in women. Despite inconclusive data are about any possible effect on myocardial infarction, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.

Methods

Study of cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea vs combination over 5—7 yr follow-up
Assessment of comparative safety
Multicentre, open-label trial of 4447 pts with type 2 diabetes on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
Randomization to addition of rosiglitazone (n=2220) or combination of metformin and sulfonylurea (active control group, n=2227)
Primary endpoint: cardiovascular hospitalization or cardiovascular death

Results

321 pts in rosiglitazone group and 323 in active control group experienced primary outcome during mean 5.5-yr follow-up, meeting criterion of non-inferiority
HR was 0.84 for cardiovascular death, 1.14 for myocardial infarction, and 0.72 for stroke
Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
Upper and distal lower limb fracture rates increased mainly in women assigned to rosiglitazone
Mean HbA1c lower in rosiglitazone vs control group at 5 yrs

Related Articles

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial)
Diabetes Care, 10/14/09 Relevance Score: 88%

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Hepatology, 11/02/09 Relevance Score: 87%

Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09 Relevance Score: 87%

Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
Cardiovascular Drug Reviews, 11/17/09 Relevance Score: 85%

Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone
American Journal of Physiology: Renal Physiology, 11/17/09 Relevance Score: 85%

Today in Diabetes...keeping you current

New therapies for the treatment of type 2 diabetes: an update
European Diabetes Nursing, 12/18/09

Consumption of restaurant foods and incidence of type 2 diabetes in African American women
American Journal of Clinical Nutrition, 12/18/09

Gestational diabetes mellitus: an opportunity to prevent Type 2 diabetes and cardiovascular disease in young women
Women's Health, 12/18/09

See all of Diabetes

Today in Pharmacology/kinetics...keeping you current

Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor
Pituitary, 12/18/09

New therapies for the treatment of type 2 diabetes: an update
European Diabetes Nursing, 12/18/09

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
Lipids in Health and Disease, 12/18/09

See all of Pharmacology/kinetics

Today in Coronary Artery Disease...keeping you current

Apolipoprotein E gene polymorphisms and serum cholesterol in healthy Irish adults: a proposed genetic marker for coronary artery disease risk
Irish Journal of Medical Science, 12/18/09

C-reactive protein for risk assessment in coronary artery disease
Heart, 12/18/09

Incidence, Risk Factors, Management and Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention
The American Journal of Cardiology, 12/18/09

See all of Coronary Artery Disease

Today in Cardiology...keeping you current

Human Parvovirus B19 Infection in Patients with Coronary Atherosclerosis
Archives of Medical Research, 12/20/09

Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Is Increased in Human Left Ventricle after Acute Myocardial Infarction
Archives of Medical Research, 12/20/09

Influence of Genetic Polymorphism in Matrix Metalloproteinase-3 on Extent of Coronary Atherosclerosis and Risk of Coronary Artery Stenosis
Archives of Medical Research, 12/20/09

See all of Cardiology

Today in Clinical Pharmacology...keeping you current

Resorption and elimination kinetics of benzoic acid during chemical necrectomy in deep burns
Scandinavian Journal of Clinical and Laboratory Investigation, 12/19/09

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/18/09

See all of Clinical Pharmacology

Today in Vascular Medicine...keeping you current

Human Parvovirus B19 Infection in Patients with Coronary Atherosclerosis
Archives of Medical Research, 12/20/09

Influence of Genetic Polymorphism in Matrix Metalloproteinase-3 on Extent of Coronary Atherosclerosis and Risk of Coronary Artery Stenosis
Archives of Medical Research, 12/20/09

Association Between Serum gamma-Glutamyltransferase and Acute Ischemic Nonembolic Stroke in Elderly Subjects
Archives of Medical Research, 12/20/09

See all of Vascular Medicine